Literature DB >> 18632023

Diagnosed diabetic retinopathy in France, Italy, Spain, and the United Kingdom.

A Rubino1, M D Rousculp, K Davis, J Wang, A Girach.   

Abstract

AIM: The objective of this study was to describe the proportion and characteristics of patients diagnosed with diabetic retinopathy (DR) in France, Italy, Spain, and the United Kingdom (UK).
METHODS: To estimate the proportion of patients with type 1 and type 2 diabetes diagnosed with DR, we conducted a cross-sectional survey of general practitioners in each country using physician records. In addition, diabetes specialists were recruited in Italy and Spain. We extracted data from the medical notes of a sample of DR patients to characterize DR severity and clinical characteristics.
RESULTS: The average number of physicians per country was 41 (range: 34-49). The proportion of diagnosed DR ranged from 10.3% (95% CI, 6.7-14.0%) in Spain to 19.6% (95% CI, 16.0-23.1%) in the UK. Of 752 DR patients studied, 53.9% were male; mean age (+/-SD) was 64.2+/-12.8 years. Consistently across countries, mild non-proliferative DR was the most common severity level of diagnosed DR. Proliferative DR (PDR) ranged from 19.7% (France) to 31.5% (UK). Diabetic macular oedema was reported in approximately 10% of patients. Hypertension (73.1%), dyslipidemia (63.2%), and neuropathy (52.1%) were the most common co-morbidities.
CONCLUSIONS: Country-specific prevalence of diagnosed DR may reflect clinical management of diabetes, healthcare systems, or record-keeping accuracy. Across countries, up to 30% of DR patients had a diagnosis of PDR, which could suggest that patients are diagnosed only when their disease is advanced.

Entities:  

Mesh:

Year:  2007        PMID: 18632023     DOI: 10.1016/j.pcd.2007.02.002

Source DB:  PubMed          Journal:  Prim Care Diabetes        ISSN: 1878-0210            Impact factor:   2.459


  8 in total

1.  Topical Interferon Alpha 2b in the Treatment of Refractory Diabetic Macular Edema.

Authors:  Arash Maleki; Andrew Phillips Stephenson; Fedra Hajizadeh
Journal:  J Ophthalmic Vis Res       Date:  2020-10-25

2.  Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real-world study.

Authors:  Tunde Peto; Toks Akerele; Alexandros Sagkriotis; Sofia Zappacosta; Andreas Clemens; Usha Chakravarthy
Journal:  Diabet Med       Date:  2021-12-15       Impact factor: 4.213

3.  An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema.

Authors:  Sobha Sivaprasad; Richard C Browning; Carla Starita
Journal:  Clin Ophthalmol       Date:  2014-08-21

4.  [Prevalence and risk factors associated with diabetic retinopathy in Santander. Northern Spain].

Authors:  José María Castillo-Otí; Joaquín Cañal-Villanueva; María Teresa García-Unzueta; Ana Isabel Galván-Manso; María Rosa Callejas-Herrero; Pedro Muñoz-Cacho
Journal:  Aten Primaria       Date:  2019-05-17       Impact factor: 1.137

5.  Barriers and facilitators to diabetic retinopathy screening within Australian primary care.

Authors:  Matthew J G Watson; Peter J McCluskey; John R Grigg; Yogesan Kanagasingam; Judith Daire; Mohamed Estai
Journal:  BMC Fam Pract       Date:  2021-11-30       Impact factor: 2.497

6.  Prediction of Visual Acuity after anti-VEGF Therapy in Diabetic Macular Edema by Machine Learning.

Authors:  Ying Zhang; Fabao Xu; Zhenzhe Lin; Jiawei Wang; Chao Huang; Min Wei; Weibin Zhai; Jianqiao Li
Journal:  J Diabetes Res       Date:  2022-04-19       Impact factor: 4.061

Review 7.  Changes in the Epidemiology of Diabetic Retinopathy in Spain: A Systematic Review and Meta-Analysis.

Authors:  Pedro Romero-Aroca; Maribel López-Galvez; Maria Asuncion Martinez-Brocca; Alicia Pareja-Ríos; Sara Artola; Josep Franch-Nadal; Joan Fernandez-Ballart; José Andonegui; Marc Baget-Bernaldiz
Journal:  Healthcare (Basel)       Date:  2022-07-16

Review 8.  Diabetic macular edema: Evidence-based management.

Authors:  David J Browning; Michael W Stewart; Chong Lee
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.